Kerry has announced two biotechnology acquisitions, as it looks to expand its expertise, technology portfolio and manufacturing capabilities.
The company has reached an agreement to acquire biotechnology innovation company, c-LEcta, and has purchased Mexican enzyme manufacturer, Enmex.
German company c-LEcta specialises in precision fermentation, optimised bio-processing and bio-transformation, producing targeted enzymes and ingredients. The business is said to have a strong pipeline of functional bioactives for the food, beverage and other consumer markets.
Enmex, meanwhile, is an enzyme manufacturer located in Mexico, supplying solutions for the food, beverage and animal nutrition markets. The acquisition will extend Kerry’s fermentation and enzyme manufacturing capabilities into Latin America.
Albert McQuaid, chief science and technology officer at Kerry, said: “The food and pharmaceutical industries are on the cusp of a new wave of innovation, where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors”.
Other stories you may like to read:
© FoodBev Media Ltd 2023